

US-based BioSkrby Genomics brings single-cell technologies to Singapore and Southeast Asia

30 August 2023 | News

Strategic distribution agreement with Research Instruments expands access to BioSkrby's best-in-class single-cell multiomics portfolio throughout Southeast Asia



US-based BioSkrby Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, has announced a partnership with Research Instruments, a premier distributor for genomic and life science research products in Southeast Asia, to distribute BioSkrby's ResolveDNA and ResolveOME single cell amplification tools throughout Singapore and Southeast Asia.

Research Instruments is part of Everlife Asia, a leading Asia-focused market access and distribution group with strong capabilities in life sciences, clinical diagnostics, and analytical instrumentation operating in seven countries across Asia.

BioSkrby's ResolveDNA genome amplification technology enables researchers to accurately examine whole genomes, whole exomes, and low-input DNA samples from single cells to reveal novel insights on the molecular drivers of disease. ResolveDNA reduces biases, experimental artifacts, and poor reproducibility that are commonly associated with traditional amplification methods, resulting in increased genomic coverage at an unprecedented resolution.

ResolveOME is a first of its kind multiomic solution that combines whole genome or exome analysis with whole transcriptome analysis within each individual cell in an integrated workflow and can help investigators explore complex multiomic datasets at scale. Powered by BioSkrby's patented primary template-directed amplification (PTA) technology, ResolveOME and ResolveDNA dramatically increase genomic coverage to 97%. When coupled with BioSkrby's BaseJumper bioinformatics platform, which provides quick analysis of complex data at scale, investigators can comprehensively explore single cell multiomic data to enhance understanding of complex diseases.